InsiderClue
Stocks · Health care · Pharmaceutical Preparations

BriaCell Therapeutics Corp.

BCTX Clue Score18
British Columbia, Canada Fiscal year ends July CIK 0001610820
$3.91 -0.26% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $3.91 −44.93% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2019Net income−4.7Fiscal year 2019Fiscal year 2020Operating income−3.9Net income−4.0Fiscal year 2021Fiscal year 2021Operating income−7.0Net income−13.8Fiscal year 2022Fiscal year 2022Operating income−15.3Net income−26.8EPS, diluted−1.73Fiscal year 2023Operating income−23.3Net income−20.3EPS, diluted−1.30Fiscal year 2024Operating income−33.3Net income−4.8EPS, diluted−43.68Fiscal year 2025Operating income−27.2Net income−26.3EPS, diluted−62.19
FY2019FY2019FY2020FY2021FY2021FY2022FY2022FY2023FY2024FY2025
Operating income n/a n/a −3.9 n/a −7.0 n/a −15.3 −23.3 −33.3 −27.2
Net income −4.7 n/a −4.0 n/a −13.8 n/a −26.8 −20.3 −4.8 −26.3
Growth
EPS, diluted n/a n/a n/a n/a n/a n/a −1.73 −1.30 −43.68 −62.19

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Fiscal year 2019Fiscal year 2020Operating cash flow−1.3Fiscal year 2021Fiscal year 2021Operating cash flow−7.8Fiscal year 2022Fiscal year 2022Operating cash flow−12.5Fiscal year 2023Operating cash flow−23.7Fiscal year 2024Operating cash flow−24.1Capital expenditure−0.5Free cash flow−24.6Fiscal year 2025Operating cash flow−28.2
FY2019FY2019FY2020FY2021FY2021FY2022FY2022FY2023FY2024FY2025
Operating cash flow n/a n/a −1.3 n/a −7.8 n/a −12.5 −23.7 −24.1 −28.2
Capital expenditure n/a n/a n/a n/a n/a n/a n/a n/a −0.5 n/a
Free cash flow n/a n/a n/a n/a n/a n/a n/a n/a −24.6 n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2019Cash0.2Shareholders’ equity−0.7Fiscal year 2019Cash0.2Shareholders’ equity−0.7Fiscal year 2020Cash0.0Shareholders’ equity−2.7Fiscal year 2021Fiscal year 2021Cash57.3Shareholders’ equity27.7Fiscal year 2022Fiscal year 2022Cash41.0Shareholders’ equity10.3Fiscal year 2023Cash21.3Shareholders’ equity−3.8Fiscal year 2024Cash0.9Shareholders’ equity−2.7Fiscal year 2025Cash10.5Shareholders’ equity17.3
FY2019FY2019FY2020FY2021FY2021FY2022FY2022FY2023FY2024FY2025
Cash 0.2 0.2 0.0 n/a 57.3 n/a 41.0 21.3 0.9 10.5
Shareholders’ equity −0.7 −0.7 −2.7 n/a 27.7 n/a 10.3 −3.8 −2.7 17.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending July, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Jul 2019 FY2019 1 Aug 2019 FY2020 31 Jul 2020 FY2021 30 Jun 2021 FY2021† 31 Jul 2021 FY2022 30 Jun 2022 FY2022† 31 Jul 2022 FY2023 31 Jul 2023 FY2024† 31 Jul 2024 FY2025† 31 Jul 2025
Revenue and profit
n/a n/a 2.4 n/a 1.3 n/a n/a n/a n/a n/a
n/a n/a 1.5 n/a 3.7 n/a n/a n/a n/a n/a
n/a n/a −3.9 n/a −7.0 n/a −15.3 −23.3 −33.3 −27.2
Growth
n/a n/a n/a n/a −13.8 n/a −26.8 20.3 4.9 26.6
n/a n/a n/a 0.0 n/a 0.0 n/a n/a n/a n/a
−4.7 n/a −4.0 n/a −13.8 n/a −26.8 −20.3 −4.8 −26.3
Growth
Per share
n/a n/a n/a n/a −3.06 n/a −1.73 −1.30 −43.68 −62.19
n/a n/a n/a n/a n/a n/a −1.73 −1.30 −43.68 −62.19
Growth
n/a n/a n/a n/a 4.5 n/a 15.5 15.6 0.1 0.4
n/a 0.6 0.7 n/a 4.5 n/a 15.5 15.6 0.1 0.4
Growth +23.2% +0.8% −99.3% +285.7%

† The diluted share count jumps at 2021 and 2022 and 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 7 of 7 years on file.